Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 19;13:2052. doi: 10.1038/s41467-022-29577-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Cox regression analysis of significant arm-level CNA events for PFS. b Kaplan–Meier curves of PFS for patients with or without 12q gain (two-sided log-rank test). c Cis-effect of 12q gain on NAP1L1 in this study and CPTAC cohort. P values are derived from two-sided Spearman’s correlation test. d Kaplan–Meier curves of PFS for patients with different NAP1L1 abundances (two-sided log-rank test). e Negative correlations between NAP1L1 and CDKN1C abundances in this study and CPTAC cohort. P values are derived from two-sided Spearman’s correlation test. f Positive correlations between NAP1L1 abundances and MGPS scores in this study (two-sided Spearman’s correlation test). g Comparison of NAP1L1 abundances between tumors with different MKI67 IHC results (MKI67 positive ≥ 10%, n = 44; MKI67 positive < 10%, n = 139). P value is derived from two-sided t test. Boxplots show the median (central line), the 25–75% IQR (box limits), the ±1.5×IQR (whiskers). h Proposed model explaining the 12q gain-induced disease progression in ccRCC. i Up, 12q gains were enriched in SP group compared with LP group. P value is derived from two-sided Fisher’s exact test. Down, Kaplan–Meier curves of PFS for SP group and LP group (two-sided log-rank test). j GSEA of SP group patients compared with LP group patients. NES, normalized enrichment score. k Enrichment plots of MTORC1 signaling in the SP group and tight junction in the LP group. l Comparison of MTORC1 signaling and tight junction scores between the SP (n = 38) and LP (n = 149) groups and the associations of MTORC1 signaling and tight junction scores with PFS. P values are derived from two-sided t test. Boxplots show the median (central line), the 25–75% IQR (box limits), the ±1.5×IQR (whiskers). m Heatmap of plasma proteins significantly upregulated in SP group than LP group. Higher expressions of these proteins were associated with shorter PFS. n The area under the receiver operating characteristic (AUROC) of the 20 plasma proteins predictor.